European Urology published a clinical update in Research Highlights on 18 Feb 2026. The item focuses on Corrigendum to “Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non–muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials” [Eur. Urol. (2025)]. Review the original article for the full source wording and details.
The authors regret that, in the originally published version of this article, the following inconsistencies were identified.